X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (34035) 34035
Publication (2786) 2786
Book Review (223) 223
Book Chapter (184) 184
Conference Proceeding (44) 44
Magazine Article (38) 38
Book / eBook (23) 23
Dissertation (18) 18
Government Document (14) 14
Web Resource (9) 9
Streaming Video (5) 5
Data Set (3) 3
Reference (2) 2
Paper (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28380) 28380
hematology (13606) 13606
oncology (11812) 11812
chronic myelogenous leukemia (11360) 11360
male (11285) 11285
female (10731) 10731
index medicus (9836) 9836
adult (9457) 9457
middle aged (8938) 8938
acute myelogenous leukemia (8219) 8219
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6454) 6454
leukemia, myelogenous, chronic, bcr-abl positive - genetics (5806) 5806
aged (5773) 5773
chronic myeloid-leukemia (5052) 5052
leukemia (5002) 5002
leukemia, myelogenous, chronic, bcr-abl positive - pathology (4803) 4803
imatinib mesylate (4649) 4649
animals (4284) 4284
adolescent (4217) 4217
chronic myeloid leukemia (4011) 4011
acute myeloid-leukemia (3748) 3748
antineoplastic agents - therapeutic use (3693) 3693
cancer (3636) 3636
treatment outcome (3377) 3377
benzamides (3349) 3349
leukemia, myelogenous, chronic, bcr-abl positive - therapy (3224) 3224
fusion proteins, bcr-abl - genetics (2903) 2903
prognosis (2867) 2867
transplantation (2808) 2808
pyrimidines - therapeutic use (2774) 2774
acute lymphoblastic-leukemia (2763) 2763
bcr-abl (2700) 2700
imatinib (2630) 2630
mice (2612) 2612
child (2545) 2545
therapy (2419) 2419
piperazines - therapeutic use (2403) 2403
immunology (2269) 2269
hemic and lymphatic diseases (2245) 2245
chemotherapy (2170) 2170
cml (2139) 2139
mutation (2012) 2012
acute disease (1993) 1993
apoptosis (1986) 1986
antineoplastic combined chemotherapy protocols - therapeutic use (1982) 1982
bone marrow transplantation (1970) 1970
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (1967) 1967
research (1939) 1939
remission induction (1887) 1887
acute myeloid leukemia (1881) 1881
transplantation, homologous (1875) 1875
aged, 80 and over (1859) 1859
cell biology (1853) 1853
expression (1834) 1834
protein kinase inhibitors - therapeutic use (1794) 1794
biochemistry & molecular biology (1777) 1777
antineoplastic agents - pharmacology (1749) 1749
bone-marrow-transplantation (1718) 1718
leukemia, myeloid, acute - genetics (1684) 1684
bone-marrow transplantation (1680) 1680
care and treatment (1677) 1677
stem cells (1627) 1627
tumor cells, cultured (1588) 1588
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (1587) 1587
philadelphia-chromosome (1584) 1584
philadelphia chromosome (1579) 1579
young adult (1576) 1576
cells (1560) 1560
child, preschool (1541) 1541
recurrence (1537) 1537
hematology, oncology and palliative medicine (1530) 1530
colony-stimulating factor (1511) 1511
leukemia, myeloid, acute - drug therapy (1495) 1495
hematopoietic stem cell transplantation (1478) 1478
retrospective studies (1439) 1439
analysis (1433) 1433
cell line, tumor (1401) 1401
pharmacology & pharmacy (1385) 1385
myelogenous leukemia (1365) 1365
medicine, research & experimental (1360) 1360
risk factors (1346) 1346
stem-cell transplantation (1346) 1346
k562 cells (1324) 1324
pyrimidines - pharmacology (1319) 1319
dasatinib (1282) 1282
genetics & heredity (1280) 1280
apoptosis - drug effects (1276) 1276
time factors (1273) 1273
drug resistance, neoplasm (1259) 1259
genetic aspects (1258) 1258
survival rate (1253) 1253
survival analysis (1248) 1248
karyotyping (1235) 1235
leukemia, myeloid, acute - pathology (1235) 1235
disease-free survival (1225) 1225
health aspects (1221) 1221
protein-tyrosine kinases - antagonists & inhibitors (1216) 1216
aml (1200) 1200
fusion proteins, bcr-abl - metabolism (1196) 1196
medicine, general & internal (1194) 1194
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (31419) 31419
Japanese (559) 559
Chinese (526) 526
German (343) 343
French (326) 326
Russian (298) 298
Spanish (255) 255
Polish (140) 140
Italian (73) 73
Korean (67) 67
Hungarian (46) 46
Czech (43) 43
Portuguese (29) 29
Danish (19) 19
Dutch (15) 15
Norwegian (9) 9
Romanian (9) 9
Serbian (9) 9
Turkish (9) 9
Ukrainian (9) 9
Croatian (7) 7
Hebrew (7) 7
Finnish (6) 6
Swedish (6) 6
Slovak (5) 5
Bulgarian (3) 3
Persian (2) 2
Slovenian (2) 2
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2013, ISBN 1615190678, xiii, 303 p., [8] p. of plates
Book
2001, 1, ISBN 185317890X, xv, 528
In this volume, an international team of experts in chronic myeloid leukemia share their expertise. In particular, they contribute their insights on the latest... 
Treatment | Leukemia, Myeloid | Acute myeloid leukemia | therapy | Clinical & internal medicine | Acute myelocytic leukaemia | Hematology | Oncology | Acute myelocytic leukemia
Book
1999, Basic and clinical oncology, ISBN 9780824799014, Volume 16, xi, 442
Book
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
2007, Contemporary hematology, ISBN 9781588296214, xiv, 426
Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The... 
Acute myeloid leukemia | Leukemia, Myelocytic, Acute | Clinical & internal medicine | Hematology | Oncology | Cancer Research | Internal Medicine | Medicine & Public Health
Book
2008, Hematologic malignancies, ISBN 3540723021, x, 294
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. Thus, several... 
Acute leukemia -- Treatment | Acute leukemia | Clinical & internal medicine
Book
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 298 - 305
Journal Article
2001, Cancer treatment and research, ISBN 9780792373964, Volume 108., xiv, 278
Book
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 06/2009, Volume 23, Issue 6, pp. 1054 - 1061
Journal Article
Cancer Cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | CHRONIC MYELOGENOUS LEUKEMIA | DASATINIB BMS-354825 | MESYLATE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | AMN107 | IMATINIB RESISTANCE | NILOTINIB | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article